Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. - Wikidata - wikimedia - TriplyDB

Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation.

Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation.

http://www.wikidata.org/entity/Q35802323

about

DNA and the chromosome - varied targets for chemotherapy Adding pharmacogenomics to the development of new marine-derived anticancer agents Evaluation of Biosynthetic Pathway and Engineered Biosynthesis of Alkaloids Marine Natural Products as Models to Circumvent Multidrug Resistance Protein Recognition in Drug-Induced DNA Alkylation: When the Moonlight Protein GAPDH Meets S23906-1/DNA Minor Groove Adducts Cancer wars: natural products strike back Trabectedin for advanced soft tissue sarcomas: optimizing use Pregnane X receptor and natural products: beyond drug-drug interactions Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.Reversing multidrug resistance by RNA interference through the suppression of MDR1 gene in human hepatoma cells.Role of trabectedin in the treatment of soft tissue sarcoma Mechanism targeted discovery of antitumor marine natural products.New agents in cancer clinical trials.Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3.Preclinical and clinical results with the natural marine product ET-743.Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.Improving cancer chemotherapy with modulators of ABC drug transporters.Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children.Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.New therapies in soft tissue sarcoma.Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.Educational paper. The development of new therapies for pediatric oncology.NF-Y and the transcriptional activation of CCAAT promoters.Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics.Trabectedin for the treatment of breast cancer.Unique features of trabectedin mechanism of action.Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line.Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway.Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1.Targeting the EWS-FLI1 transcription factor in Ewing sarcoma.Transcriptional inhibition of type I collagen gene expression in scleroderma fibroblasts by the antineoplastic drug ecteinascidin 743.Optimal management of uterine leiomyosarcoma.Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis.Mode of action of trabectedin in myxoid liposarcomas.

P2860

Q24792540-885923E6-0D82-43AA-9E19-6B701A099C40 Q25254985-2283F082-AB6A-40E8-B880-67205E72935A Q26739981-1BF33B97-8F24-4A71-B2A5-384575B1F81C Q26741330-86055C8E-0ADA-4261-958D-718C0FCFF195 Q26778143-15D4A32F-9DAD-41C1-AEFF-B8571B5190FE Q26850074-72EBB25C-98FC-4669-9C65-B20045D95DEA Q26860365-83374784-8AE8-4426-AF7B-67A57E95FA7D Q28748504-469FACE8-3AA9-4BE2-B977-6C3A3B46CBE5 Q33377399-6490879D-1241-47B0-8EC1-22827AB08DEA Q33868054-92A6E353-C113-4140-B293-857F005B36BA Q33916011-A9BD9FF6-5FFE-4645-9705-DE5750FAEA0A Q34012630-E6A3DD27-CBC4-4F53-8550-F0F984C3B494 Q34293629-FBA34C84-B3B7-4D66-ABD7-ED3E0D6BC39D Q34347410-2529342D-8B2A-403E-A6EC-A9CCCCD5D8A6 Q34542908-C531A008-F9DF-44D1-9766-1BE70DD08284 Q35166852-4B27ED80-381A-4317-8A2B-FAF3781A5AF1 Q35676502-C5097E32-5EFD-42FF-A8B7-E9709C83CE57 Q35802653-621FCF9B-3E8C-4323-A3C9-DB67D8CF3D11 Q36108251-9A08AFD7-0370-452E-91C2-3C0A243047D7 Q36432104-5BAE1BB2-8869-45E2-A294-58987DE30B68 Q36616537-918D574F-2807-4ED2-8069-049AC82E220F Q37010772-1F29A78E-23EB-4922-8BB0-1C94E362366D Q37750812-C5B17BF3-1F7A-4BC5-B8F1-D0E8C82E51A6 Q37760957-FFA674AA-052F-4980-AFEC-182E47A7CFB4 Q37824438-45D6B702-94F3-4CA0-A3A4-A1505DF6CCA2 Q37952284-3410D8F6-F1FC-43AB-AFF4-DA6F63B73B2B Q38206366-7B933415-F815-4F2A-BC75-5ABAFC90F223 Q38255906-33F9A88A-EEC3-4F6C-B628-324B83950ABD Q38642314-EC552CE0-7A87-4B5E-96CF-E1BD7E6C5DE0 Q38669051-0B8697C2-C1FB-4BF6-99EB-A77814201F0F Q38728270-3B18A6A1-4801-4007-85B3-ED20C1357BAF Q39111478-82C9EAE6-6754-444E-BD29-C4EF22713E8A Q39497253-EC0F9A17-445D-42C0-82A6-6D9022A88A97 Q40381466-B333346D-841D-4545-BC78-7D55E96EB06B Q40507972-DCF8E0C7-EE36-41C8-A8B3-D32ABC4E4D55 Q41159521-78798BAB-C92F-42F8-8CCF-18DEC2652936 Q42798947-D274B317-A56F-45FE-B461-9F5EDA09F38C Q43173702-218ECF4F-154D-4D35-804B-B9AD32279F67 Q44116130-30BD325D-FB15-4C60-BC5F-BD95D2639996 Q45346605-AF76ADCF-B669-476D-8FDA-6054EB561C36

P2860

Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation.

http://www.wikidata.org/entity/Q35802323

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

2000年论文

@zh

2000年论文

@zh-cn

name

Ecteinascidin 743, a transcrip ...... that inhibits MDR1 activation.

@ast

Ecteinascidin 743, a transcrip ...... that inhibits MDR1 activation.

@en

type

label

Ecteinascidin 743, a transcrip ...... that inhibits MDR1 activation.

@ast

Ecteinascidin 743, a transcrip ...... that inhibits MDR1 activation.

@en

prefLabel

Ecteinascidin 743, a transcrip ...... that inhibits MDR1 activation.

@ast

Ecteinascidin 743, a transcrip ...... that inhibits MDR1 activation.

@en

P1433

Q35802323-D303C9A9-B23A-45FE-8CAC-85A046DBB54B

P1476

Q35802323-DF288A58-4D5D-4FE6-AD8A-DF28035B3E06

P2093

Q35802323-07EE08B6-AC95-4E59-BBB7-D9E62F97E1F1

Q35802323-40570B11-8484-461C-B3BC-7339FC9A889E

Q35802323-487FFAC2-1AF7-4FBE-B9AE-7CFA34C9B991

Q35802323-8CCE0029-0061-4EAD-9052-F8A82730CDD6

P2860

Q35802323-0F30B632-3ACE-4670-B083-480C1D930199

Q35802323-2507608A-EFC5-49B0-A28B-9B1C9A3520C9

Q35802323-39387886-192A-4255-9D08-CBA474A6448F

Q35802323-4703F9AD-9951-42FA-A609-6E07991EB0A6

Q35802323-4DA7DCF0-FE36-4EE5-8359-5E4647616702

Q35802323-5B2A1CEE-2E2D-4EAF-BA6D-904DAFE9270D

Q35802323-5C597C65-1192-4BF5-AFA5-8666A8B89E8B

Q35802323-6F8B9827-CE2C-45A2-A954-9C21577D239D

Q35802323-93BD6EC3-36EE-4244-8EE3-B73AB40D44A7

Q35802323-A4EC1530-8645-4A2B-9B21-AEE74069F555

P304

Q35802323-23B3ED14-08E8-4F57-BABD-73C0258DAA0A

P31

Q35802323-13B9C146-B44F-48D9-AC4E-7EC915B697E0

P356

Q35802323-6F7806BE-0378-41CC-99B9-85A5473E202D

P407

Q35802323-2D7AE6DF-CA02-4FB0-8AF0-179A0BD8160F

P433

Q35802323-7F350CE8-BFF0-4C24-958D-08B074AEF4CE

P478

Q35802323-57207A49-F457-47F1-91CF-2A9BE1529D88

P577

Q35802323-2A5990CF-1A9F-4099-8F6F-8630127565A5

P5875

Q35802323-124A293E-B01F-4CF7-93F4-F6BFEE7646F9

P698

Q35802323-136E73D0-1CD5-4124-9CF3-499E6CE73B4C

P921

Q35802323-0F6364DB-DAFA-4196-8F50-5DA34BC389D7

P932

Q35802323-A069BEFD-1470-4C51-9BDD-8969CE58CA95

P356

PNAS.97.12.6775

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Ecteinascidin 743, a transcrip ...... that inhibits MDR1 activation.

@en

P2093

B Gorfajn

http://www.w3.org/2001/XMLSchema#string

G Faircloth

http://www.w3.org/2001/XMLSchema#string

K W Scotto

http://www.w3.org/2001/XMLSchema#string

S Jin

http://www.w3.org/2001/XMLSchema#string

P2860

The 400 kDa subunit of the PCAF histone acetylase complex belongs to the ATM superfamily

Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A

Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y.

Xenopus NF-Y pre-sets chromatin to potentiate p300 and acetylation-responsive transcription from the Xenopus hsp70 promoter in vivo

Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove.

Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA.

Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.

Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove.

Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743.

The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis.

P304

6775-6779

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.97.12.6775

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P577

2000-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12475885

http://www.w3.org/2001/XMLSchema#string

P698

10841572

http://www.w3.org/2001/XMLSchema#string

P921

P932

18735

http://www.w3.org/2001/XMLSchema#string